English

Pyxis Oncology, Inc.

EDGAR

PYXS Registration statement (S-3) · filed 2026-08-20

Annual consolidated revenue for 2025: about USD 13.86M, using the latest reported figures. The previous period, 2024, was about USD 16.15M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

11 million USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 13858000 USD Source
Revenue: 2820000 USD Source

Operating margin

-165.75%

2025 Q4 · %

Exact inputs and evidence

Operating Income: -84420000 USD Source
Operating Income: -66125000 USD Source
Revenue: 13858000 USD Source
Revenue: 2820000 USD Source

Operating cash flow

-10.4 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -63502000 USD Source
Operating Cash Flow: -53075000 USD Source

Free cash flow

-10.4 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -63502000 USD Source
Operating Cash Flow: -53075000 USD Source
Capital Expenditure: 9000 USD Source
Capital Expenditure: 9000 USD Source

Cash and cash equivalents: 18.9 million USD 2026-06-30 Source
Exact value

18855000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 63.4 million shares 2026-06-30 Source
Exact value

63434936 shares

Reported share-count change

2.28% · 1.42 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

62018135 shares · 2025-06-30· Source
63434936 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-88.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -22003000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -79621000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -61500000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -23272000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -25300000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-67.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -53075000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -39798000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -63502000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -53075000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -26000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -44206000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -26000000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-20.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 2 of 11 periods available· newest 2025-12-31
Total liabilities: 2 of 11 periods available· newest 2025-12-31
Current assets: 2 of 11 periods available· newest 2025-12-31
Current liabilities: 2 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-14.2%

Prior period

USD 16.15 million

2024-01-01 – 2024-12-31
Current period

USD 13.86 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

13858000 − 16146000 = -2288000 USD

16146000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
13858000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Year-over-year change in Revenue: -2288000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 13858000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#1948691 Filing: 000119312526118532 Input fundies:Revenue: 16146000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#1950292 Filing: 000119312526118532
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 2.29 million

Prior period

−USD 77.33 million

2024-01-01 – 2024-12-31
Current period

−USD 79.62 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-79621000 − -77331000 = -2290000 USD

-77331000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-79621000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Year-over-year change in Net income: -2290000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -79621000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#3585704 Filing: 000119312526118532 Input fundies:NetIncome: -77331000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#3587451 Filing: 000119312526118532
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 5.83 million

Prior period

−USD 57.67 million

2024-01-01 – 2024-12-31
Current period

−USD 63.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-63502000 − -57672000 = -5830000 USD

-57672000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-63502000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Year-over-year change in Operating cash flow: -5830000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -63502000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2343821 Filing: 000119312526118532 Input fundies:OperatingCashFlow: -57672000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2345730 Filing: 000119312526118532
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-96.2%

Prior period

USD 237,000

2024-01-01 – 2024-12-31
Current period

USD 9,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

9000 − 237000 = -228000 USD

237000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
9000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Year-over-year change in Capital expenditure: -228000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 9000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2358458 Filing: 000119312526118532 Input fundies:CapitalExpenditure: 237000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2360302 Filing: 000119312526118532
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 13.86 million 100% of revenue
Operating costs Derived USD 98.28 million 709% of revenue
Operating income −USD 84.42 million −609% of revenue
Tax, interest and other Derived −USD 4.8 million −35% of revenue
Net income −USD 79.62 million −575% of revenue

Cash

Operating cash flow −USD 63.5 million −458% of revenue
Capital expenditure USD 9,000 0.1% of revenue
Free cash flow Derived −USD 63.51 million −458% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2024 Operating loss: operating costs were 654% of revenue.
2025 Operating loss: operating costs were 709% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2024 2024-01-01 – 2024-12-31	16146000	105606000 Derived	-89460000	-12129000 Derived	-77331000	-57909000 Derived	Source 2024-01-01 – 2024-12-31: 16146000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -89460000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -77331000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -57672000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 237000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	13858000	98278000 Derived	-84420000	-4799000 Derived	-79621000	-63511000 Derived	Source 2025-01-01 – 2025-12-31: 13858000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -84420000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -79621000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -63502000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 9000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 13.9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Revenue	16146000	Revenue: 16146000 Open source
20252025-12-31	Revenue	13858000	Revenue: 13858000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-14.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Year over year	No prior comparable period	Revenue: 16146000 Open source
20252025-12-31	Year over year	-14.2%	Revenue: 13858000 Open source Revenue: 16146000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -609.2% 2025

Net margin -574.5% 2025

Free cash flow margin -458.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Operating margin	-554.1%	Operating Income: -89460000 Open source Revenue: 16146000 Open source
20252025-12-31	Operating margin	-609.2%	Operating Income: -84420000 Open source Revenue: 13858000 Open source
20242024-12-31	Net margin	-478.9%	Net Income: -77331000 Open source Revenue: 16146000 Open source
20252025-12-31	Net margin	-574.5%	Net Income: -79621000 Open source Revenue: 13858000 Open source
20242024-12-31	Free cash flow margin	-358.7%	Revenue: 16146000 Open source Operating Cash Flow: -57672000 Open source Capital Expenditure: 237000 Open source
20252025-12-31	Free cash flow margin	-458.3%	Revenue: 13858000 Open source Operating Cash Flow: -63502000 Open source Capital Expenditure: 9000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -63.5M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Operating cash flow	-57672000	Operating Cash Flow: -57672000 Open source
20252025-12-31	Operating cash flow	-63502000	Operating Cash Flow: -63502000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -63.5M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Free cash flow	-57909000	Operating Cash Flow: -57672000 Open source Capital Expenditure: 237000 Open source
20252025-12-31	Free cash flow	-63511000	Operating Cash Flow: -63502000 Open source Capital Expenditure: 9000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

41.6% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Liabilities / assets	23.2%	Total Liabilities: 36430000 Open source Total Assets: 157181000 Open source
20252025-12-31	Liabilities / assets	41.6%	Total Liabilities: 38112000 Open source Total Assets: 91520000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.41× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Current assets / current liabilities	7.49×	Current Assets: 132440000 Open source Current Liabilities: 17680000 Open source
20252025-12-31	Current assets / current liabilities	3.41×	Current Assets: 72105000 Open source Current Liabilities: 21131000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 12.83 million Exact value Exact value: -12828000 USD 2020-01-01 – 2020-12-31: -12828000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pyxis Oncology, Inc. · 2020-12-31 Pyxis Oncology, Inc. (edgar:1782223) Net Income: -12828000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12828000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017022004850/pyxs-20211231.htm#3215263 Filing: 000095017022004850 The citation records this snapshot. The page link may show a newer release later.	−USD 10.08 million Exact value Exact value: -10084000 USD 2020-01-01 – 2020-12-31: -10084000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pyxis Oncology, Inc. · 2020-12-31 Pyxis Oncology, Inc. (edgar:1782223) Operating Cash Flow: -10084000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10084000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017022004850/pyxs-20211231.htm#2407994 Filing: 000095017022004850 The citation records this snapshot. The page link may show a newer release later.	USD 1.48 million Exact value Exact value: 1483000 USD 2020-01-01 – 2020-12-31: 1483000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pyxis Oncology, Inc. · 2020-12-31 Pyxis Oncology, Inc. (edgar:1782223) Capital Expenditure: 1483000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1483000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017022004850/pyxs-20211231.htm#2415175 Filing: 000095017022004850 The citation records this snapshot. The page link may show a newer release later.	−USD 11.57 million Calculation and evidence -10084000 − 1483000 USD Exact free cash flow: -11567000 USD 2020-01-01 – 2020-12-31: -10084000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1483000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pyxis Oncology, Inc. · 2020-12-31 Pyxis Oncology, Inc. (edgar:1782223) Free cash flow: -11567000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10084000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017022004850/pyxs-20211231.htm#2407994 Filing: 000095017022004850 Input fundies:CapitalExpenditure: 1483000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017022004850/pyxs-20211231.htm#2415175 Filing: 000095017022004850 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 28.92 million Exact value Exact value: -28916000 USD 2021-01-01 – 2021-12-31: -28916000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pyxis Oncology, Inc. · 2021-12-31 Pyxis Oncology, Inc. (edgar:1782223) Net Income: -28916000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28916000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000143774923016930/pyxs20230603_s4.htm#4219467 Filing: 000143774923016930 The citation records this snapshot. The page link may show a newer release later.	−USD 23.9 million Exact value Exact value: -23902000 USD 2021-01-01 – 2021-12-31: -23902000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pyxis Oncology, Inc. · 2021-12-31 Pyxis Oncology, Inc. (edgar:1782223) Operating Cash Flow: -23902000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23902000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000143774923016930/pyxs20230603_s4.htm#4247300 Filing: 000143774923016930 The citation records this snapshot. The page link may show a newer release later.	USD 54,000 Exact value Exact value: 54000 USD 2021-01-01 – 2021-12-31: 54000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pyxis Oncology, Inc. · 2021-12-31 Pyxis Oncology, Inc. (edgar:1782223) Capital Expenditure: 54000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 54000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000143774923016930/pyxs20230603_s4.htm#4249848 Filing: 000143774923016930 The citation records this snapshot. The page link may show a newer release later.	−USD 23.96 million Calculation and evidence -23902000 − 54000 USD Exact free cash flow: -23956000 USD 2021-01-01 – 2021-12-31: -23902000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 54000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pyxis Oncology, Inc. · 2021-12-31 Pyxis Oncology, Inc. (edgar:1782223) Free cash flow: -23956000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23902000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000143774923016930/pyxs20230603_s4.htm#4247300 Filing: 000143774923016930 Input fundies:CapitalExpenditure: 54000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000143774923016930/pyxs20230603_s4.htm#4249848 Filing: 000143774923016930 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 120.72 million Exact value Exact value: -120717000 USD 2022-01-01 – 2022-12-31: -120717000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pyxis Oncology, Inc. · 2022-12-31 Pyxis Oncology, Inc. (edgar:1782223) Net Income: -120717000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -120717000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034868/pyxs-20231231.htm#3669030 Filing: 000095017024034868 The citation records this snapshot. The page link may show a newer release later.	−USD 89.34 million Exact value Exact value: -89335000 USD 2022-01-01 – 2022-12-31: -89335000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pyxis Oncology, Inc. · 2022-12-31 Pyxis Oncology, Inc. (edgar:1782223) Operating Cash Flow: -89335000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -89335000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034868/pyxs-20231231.htm#2716701 Filing: 000095017024034868 The citation records this snapshot. The page link may show a newer release later.	USD 6.4 million Exact value Exact value: 6399000 USD 2022-01-01 – 2022-12-31: 6399000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pyxis Oncology, Inc. · 2022-12-31 Pyxis Oncology, Inc. (edgar:1782223) Capital Expenditure: 6399000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6399000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034868/pyxs-20231231.htm#2729535 Filing: 000095017024034868 The citation records this snapshot. The page link may show a newer release later.	−USD 95.73 million Calculation and evidence -89335000 − 6399000 USD Exact free cash flow: -95734000 USD 2022-01-01 – 2022-12-31: -89335000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 6399000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pyxis Oncology, Inc. · 2022-12-31 Pyxis Oncology, Inc. (edgar:1782223) Free cash flow: -95734000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -89335000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034868/pyxs-20231231.htm#2716701 Filing: 000095017024034868 Input fundies:CapitalExpenditure: 6399000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034868/pyxs-20231231.htm#2729535 Filing: 000095017024034868 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 73.79 million Exact value Exact value: -73790000 USD 2023-01-01 – 2023-12-31: -73790000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pyxis Oncology, Inc. · 2023-12-31 Pyxis Oncology, Inc. (edgar:1782223) Net Income: -73790000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73790000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040771/pyxs-20241231.htm#3345311 Filing: 000095017025040771 The citation records this snapshot. The page link may show a newer release later.	−USD 70.71 million Exact value Exact value: -70709000 USD 2023-01-01 – 2023-12-31: -70709000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pyxis Oncology, Inc. · 2023-12-31 Pyxis Oncology, Inc. (edgar:1782223) Operating Cash Flow: -70709000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70709000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040771/pyxs-20241231.htm#2169348 Filing: 000095017025040771 The citation records this snapshot. The page link may show a newer release later.	USD 6.73 million Exact value Exact value: 6726000 USD 2023-01-01 – 2023-12-31: 6726000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pyxis Oncology, Inc. · 2023-12-31 Pyxis Oncology, Inc. (edgar:1782223) Capital Expenditure: 6726000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6726000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040771/pyxs-20241231.htm#2186255 Filing: 000095017025040771 The citation records this snapshot. The page link may show a newer release later.	−USD 77.44 million Calculation and evidence -70709000 − 6726000 USD Exact free cash flow: -77435000 USD 2023-01-01 – 2023-12-31: -70709000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 6726000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pyxis Oncology, Inc. · 2023-12-31 Pyxis Oncology, Inc. (edgar:1782223) Free cash flow: -77435000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70709000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040771/pyxs-20241231.htm#2169348 Filing: 000095017025040771 Input fundies:CapitalExpenditure: 6726000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040771/pyxs-20241231.htm#2186255 Filing: 000095017025040771 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 77.33 million Exact value Exact value: -77331000 USD 2024-01-01 – 2024-12-31: -77331000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pyxis Oncology, Inc. · 2024-12-31 Pyxis Oncology, Inc. (edgar:1782223) Net Income: -77331000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -77331000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#3587451 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.	−USD 57.67 million Exact value Exact value: -57672000 USD 2024-01-01 – 2024-12-31: -57672000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pyxis Oncology, Inc. · 2024-12-31 Pyxis Oncology, Inc. (edgar:1782223) Operating Cash Flow: -57672000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57672000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2345730 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.	USD 237,000 Exact value Exact value: 237000 USD 2024-01-01 – 2024-12-31: 237000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pyxis Oncology, Inc. · 2024-12-31 Pyxis Oncology, Inc. (edgar:1782223) Capital Expenditure: 237000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 237000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2360302 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.	−USD 57.91 million Calculation and evidence -57672000 − 237000 USD Exact free cash flow: -57909000 USD 2024-01-01 – 2024-12-31: -57672000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 237000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pyxis Oncology, Inc. · 2024-12-31 Pyxis Oncology, Inc. (edgar:1782223) Free cash flow: -57909000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57672000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2345730 Filing: 000119312526118532 Input fundies:CapitalExpenditure: 237000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2360302 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 79.62 million Exact value Exact value: -79621000 USD 2025-01-01 – 2025-12-31: -79621000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Net Income: -79621000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -79621000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#3585704 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.	−USD 63.5 million Exact value Exact value: -63502000 USD 2025-01-01 – 2025-12-31: -63502000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Operating Cash Flow: -63502000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63502000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2343821 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.	USD 9,000 Exact value Exact value: 9000 USD 2025-01-01 – 2025-12-31: 9000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Capital Expenditure: 9000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2358458 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.	−USD 63.51 million Calculation and evidence -63502000 − 9000 USD Exact free cash flow: -63511000 USD 2025-01-01 – 2025-12-31: -63502000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 9000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pyxis Oncology, Inc. · 2025-12-31 Pyxis Oncology, Inc. (edgar:1782223) Free cash flow: -63511000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782223?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63502000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2343821 Filing: 000119312526118532 Input fundies:CapitalExpenditure: 9000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm#2358458 Filing: 000119312526118532 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

28 filings · 1,344 latest values · 1,344 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001782223, 1782223, PYXS, edgar:1782223

Also known as Pyxis Oncology, Inc.

Pyxis Oncology, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation